BioXmark® – Clinical activities:
Completed: Esophagus and Lung
Ongoing: Bladder and Rectum
Planned: Breast, Liver, Pancreas and Prostate
BioXmark® has prevoiusly been evaluated in two investigator initiated clinical trials at the Copenhagen University Hospital (Rigshospitalet).
One trial included 15 patients with locally advanced non-small cell lung cancer (NSCLC) and demonstrated BioXmark® to perform as anticipated when used as a tissue marker to guide radiotherapy. The patients enrolled in the trial have continued in an ongoing follow-up study phase with annual reporting.
Another trial evaluated BioXmark® as a tissue marker to guide radiotherapy of esophageal cancer.
Results from both studies have been published. Please see our Publication list
Two investigator initiated clinical trials are currently ongoing;
- BioXmark liquid fiducials to enable radiotherapy tumor boosting in rectal cancer, a feasibility trial – conducted by Maastro Clinic in the Netherlands
- BioXmark liquid fiducial markers for image guided radiotherapy in bladder cancer, a safety and performance trial – conducted by Amsterdam Medical Center in the Netherlands.